For medical device manufacturers operating in the European Union, regulatory compliance is essential to maintaining market access. With the November 28, 2026, EUDAMED registration deadline approaching, companies should confirm that their applicable devices are properly registered and that the information supporting those registrations is accurate and current.
The European Database on Medical Devices (EUDAMED) represents an important step toward greater transparency, traceability, and regulatory oversight across the EU medical device market.
For manufacturers, however, EUDAMED is more than another regulatory database. It introduces additional expectations for how device information is managed, maintained, and communicated throughout the product lifecycle.
The immediate priority is determining which devices require registration, identifying outstanding information, and completing applicable registrations before the deadline.
Understanding the November 2026 Deadline
The European Commission's implementation of EUDAMED reached a significant milestone on May 28, 2026, when four of its six modules became mandatory:
- Actor Registration: Registration of applicable economic operators, including manufacturers, authorized representatives, and importers.
- UDI/Device Registration: Registration of applicable medical devices and in vitro diagnostic devices, including required identification and regulatory information.
- Notified Bodies and Certificates: Registration and management of applicable notified body and certification information.
- Market Surveillance: A system supporting regulatory authorities in monitoring devices available on the EU market.
The November 28, 2026, deadline is particularly important for manufacturers with qualifying medical devices and in vitro diagnostic devices first placed on the EU market before May 28, 2026, where additional units continue to be placed on the market on or after that date.
Devices first placed on the market on or after May 28, 2026, that are subject to EUDAMED device registration generally must be registered before being placed on the market.
Manufacturers should carefully evaluate their product portfolios because registration requirements depend on device status, applicable regulations, and continued market placement. Not every device previously sold in the EU is automatically subject to the November transition deadline.
Why EUDAMED Registration Matters to Your Business
EUDAMED was established under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) to improve regulatory transparency and strengthen device traceability.
While these objectives support patient safety and regulatory oversight, they also carry practical implications for manufacturers.
Maintaining EU Market Access
Failure to complete required registrations may create regulatory compliance concerns and potential disruptions to market access. Manufacturers should ensure their registration obligations are understood and addressed before outstanding issues become more difficult to resolve.
Improving Regulatory Transparency
EUDAMED makes certain information about medical devices and economic operators publicly accessible. Accurate registration information helps support confidence among regulatory authorities, distributors, healthcare organizations, and other stakeholders.
Strengthening Device Traceability
The database connects device identification information with relevant regulatory records. This supports improved visibility into devices placed on the EU market and reinforces the importance of maintaining accurate product information.
Supporting Long-Term Regulatory Compliance
EUDAMED registration is not a one-time administrative activity. As products evolve, manufacturers must assess whether changes to device information, regulatory status, or other relevant details require corresponding database updates.
Five Areas Manufacturers Should Review Before the Deadline
With limited time remaining, manufacturers should focus on identifying registration gaps and resolving issues that could prevent successful completion.
1. Confirm Which Products Require Registration
Begin with a review of the devices currently being placed on the EU market.
Determine which products fall within the November 2026 transition requirements and whether any exclusions or exceptions apply.
This assessment should consider device classification, regulatory status, applicable MDR or IVDR requirements, and whether additional units continue to be placed on the market.
2. Verify Device Identification Information
Accurate device identification is fundamental to successful EUDAMED registration.
Manufacturers should review applicable Basic UDI-DI and UDI-DI information, ensuring consistency with labeling, technical documentation, and regulatory records.
Discrepancies between these sources should be investigated and corrected before submission.
3. Review Authorized Representative and Economic Operator Information
Manufacturers located outside the European Union should verify that their applicable EU Authorized Representative information is accurate and that required actor registrations are complete.
Coordination among manufacturers, authorized representatives, and other relevant economic operators can help identify missing information and clarify responsibilities.
4. Confirm Documentation and Certificate Alignment
Device registration information should accurately reflect the applicable regulatory documentation.
Manufacturers should review relevant declarations of conformity, certificates, device classifications, and technical documentation to identify inconsistencies that may affect registration.
Where necessary, questions regarding notified body certificates should be coordinated with the responsible notified body.
5. Establish Responsibility for Ongoing Maintenance
Completing an initial registration is only part of the process.
Manufacturers should establish clear internal responsibilities for reviewing EUDAMED information and maintaining accurate records as products and regulatory requirements change.
Integrating these activities into existing Quality Management System (QMS) procedures can help support consistent compliance over time.
The Connection Between EUDAMED and Your Quality Management System
One of the most important considerations for manufacturers is the relationship between EUDAMED registration and their existing QMS.
Information submitted to EUDAMED should be consistent with the documentation maintained throughout the product lifecycle.
Changes to device identification, labeling, regulatory status, or other relevant product information may affect registration records and should be evaluated through established change control procedures.
A well-structured QMS helps manufacturers establish accountability, maintain documentation consistency, and identify when regulatory information requires updating.
By incorporating EUDAMED responsibilities into existing quality processes, manufacturers can reduce administrative inconsistencies and support a more sustainable approach to regulatory compliance.
What Happens After November 2026?
Although the November deadline is an immediate priority, EUDAMED implementation will continue beyond 2026.
The European Commission has established additional transitional requirements, including a May 28, 2027, deadline for the registration of certain MDR and IVDR certificates issued before the mandatory implementation of the Notified Bodies and Certificates module.
The remaining EUDAMED modules, covering Vigilance and Post-Market Surveillance and Clinical Investigations and Performance Studies, will become mandatory according to their applicable implementation schedules.
Manufacturers should therefore view current registration activities as part of a broader effort to maintain regulatory readiness.
Organizations that establish reliable data management practices now may be better positioned to address future EUDAMED requirements.
How RQMIS Can Support Your EUDAMED Readiness
Navigating evolving EU regulatory requirements can be challenging, particularly for manufacturers managing multiple products, device classifications, or international markets.
Since 1996, RQMIS has supported medical product companies with regulatory strategy, quality management systems, technical documentation, and international market access.
With operations in the United States, United Kingdom, and European Union, RQMIS provides regulatory and quality support to manufacturers seeking to establish and maintain compliance across multiple markets.
Our team can assist manufacturers with:
- Assessing applicable EUDAMED registration requirements and identifying potential compliance gaps.
- Reviewing device portfolios and associated regulatory documentation.
- Evaluating the consistency of device identification and registration information.
- Supporting coordination of regulatory responsibilities with EU Authorized Representatives and other relevant parties.
- Integrating EUDAMED registration maintenance into existing QMS and change control processes.
- Providing ongoing EU regulatory and quality management support.
Whether your organization needs assistance evaluating its registration obligations or strengthening its broader EU compliance processes, RQMIS can help identify practical next steps.
November 28 Is Approaching. Is Your Organization Prepared?
The November 2026 EUDAMED deadline is an important reminder that regulatory readiness requires accurate information, coordinated responsibilities, and effective quality management processes.
Manufacturers should use the remaining time to verify their registration status, resolve outstanding discrepancies, and confirm that applicable requirements have been addressed.
RQMIS recommends completing required registrations by November 27, 2026, to allow a practical margin before the official deadline.
Taking action now can help reduce avoidable compliance risks and establish a stronger foundation for ongoing participation in the European medical device market.
Contact RQMIS today to discuss your EUDAMED registration requirements and learn how our regulatory and quality management experts can support your EU market access objectives.